Literature DB >> 8785407

Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid.

V Pichette1, P du Souich.   

Abstract

The site where furosemide is metabolized and the location where probenecid reduces furosemide metabolism remain poorly defined. The liver appears to play a minor role, and there is indirect evidence suggesting that the kidneys could be responsible for the metabolism of furosemide. To assess the role of the kidneys in the metabolism of furosemide, its intravenous kinetics have been studied in control and anephric rabbits, after the ligation of the renal pedicles. Two additional groups of rabbits, control and anephric, have received probenecid before the administration of furosemide. In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively. In anephric rabbits, total clearance was reduced by 85% to 2.69 +/- 0.26 mL/min per kg (P < 0.001), secondary to the abolition of furosemide renal excretion and to the reduction in metabolic clearance from 10.70 +/- 1.11 to 2.69 +/- 0.26 mL/min per kg (P < 0.001). The pretreatment with probenecid reduced the total clearance of furosemide by 80%, to 3.62 +/- 0.24 mL/min per kg (P < 0.001), because of a reduction of 90 and 75% in urinary and metabolic clearances, respectively. The administration of probenecid to anephric rabbits did not reduce further the metabolic clearance. It is concluded that the kidneys are responsible for 85% of furosemide total clearance, either via excretion (43%) or biotransformation (42%), and that probenecid inhibits both processes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8785407     DOI: 10.1681/ASN.V72345

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  8 in total

1.  Favorable effect on postgraduate clinical practice of a drug-interaction exercise for undergraduate students.

Authors:  Shuichi Tsuruoka; Atsuhiro Kawaguchi; Kazuhiro Harada; Akio Fujimura
Journal:  Eur J Clin Pharmacol       Date:  2006-05-23       Impact factor: 2.953

2.  Perinatal growth restriction decreases diuretic action of furosemide in adult rats.

Authors:  Barent N DuBois; Jacob Pearson; Tahir Mahmood; Duc Nguyen; Kent Thornburg; Ganesh Cherala
Journal:  Eur J Pharmacol       Date:  2014-02-05       Impact factor: 4.432

3.  Net secretion of furosemide is subject to indomethacin inhibition, as observed in Caco-2 monolayers and excised rat jejunum.

Authors:  S D Flanagan; L Z Benet
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

Review 4.  Furosemide as a functional marker of acute kidney injury in ICU patients: a new role for an old drug.

Authors:  Filippo Mariano; Alberto Mella; Marco Vincenti; Luigi Biancone
Journal:  J Nephrol       Date:  2019-05-14       Impact factor: 3.902

5.  Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.

Authors:  Katherine L Gill; Michael Gertz; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2013-01-09       Impact factor: 3.922

Review 6.  Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.

Authors:  Aikaterini Zisaki; Ljubisa Miskovic; Vassily Hatzimanikatis
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

7.  Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis.

Authors:  Tao Han Lee; George Kuo; Chih-Hsiang Chang; Yen Ta Huang; Chieh Li Yen; Cheng-Chia Lee; Pei Chun Fan; Jia-Jin Chen
Journal:  PLoS One       Date:  2021-12-01       Impact factor: 3.240

8.  Warfarin Pharmacogenomics for Precision Medicine in Real-Life Clinical Practice in Southern Africa: Harnessing 73 Variants in 29 Pharmacogenes.

Authors:  Sarudzai Muyambo; Arinao Ndadza; Nyarai D Soko; Bianca Kruger; Gerard Kadzirange; Emile Chimusa; Collen M Masimirembwa; Mpiko Ntsekhe; Charles F B Nhachi; Collet Dandara
Journal:  OMICS       Date:  2021-12-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.